Your Annual Industry Touchpoint to Maximize the Therapeutic of Your ADC
Accelerate Your Antibody-Drug Conjugate Pipeline to Become a Front-Line Treatment
Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and Astellas’ PADCEV, all alongside a frenzy of companies entering the field and billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond, ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking.
Returning as industry’s definitive ADC forum from early discovery to late-phase manufacturing, the 15th World ADC San Diego is the world-leading, largest, and most comprehensive ADC-focused conference to maximize the therapeutic window of ADCs. Whether you have just ventured into the ADC space or are an ADC guru, you’ll leave this meeting with the insight and connections needed to overcome your challenges and make impactful strides in your work.
FULL EVENT GUIDE
Uniting over 1,200 ADC enthusiasts from field novices to long-standing KOLs including experts from Daiichi Sankyo, Pfizer, AbbVie, AstraZeneca, and ADC Therapeutics, World ADC San Diego is the annual community touchpoint to gain unparalleled knowledge across cutting-edge R&D, end-to-end development strategy, and global market trends to progress ADCs to new standard of care treatments in oncology and beyond.
Previous Attending Companies Include...
Cutting-Edge, End-to-End Scientific Content for All Stages of ADC Development
From new members to long-standing experts in the ADC field, our program has you covered:
Your 140+ World Class Speakers Include:
Ahsan Arozullah
Senior Vice President, Head of Oncology Development
Astellas Innovation Management LLC
Puja Sapra
Senior Vice President, Biologics Engineering and Oncology Targeted Discovery, Oncology R&D
AstraZeneca
Proud to Partner With:
Lead Partner
Senior Partners
Partners
Exhibitors
